News | June 03, 2021
Haffkine Biopharma to produce 22.8 Cr doses of Covaxin
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
Aurobindo has one of the most enduring generics ecosystems among peers
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
7.94 crore doses were made available to the states in May 2021
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
Subscribe To Our Newsletter & Stay Updated
